Business Context and Reporting Period
Company: SciSparc Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: August 2022 (Report No. 8)
Date Filed: August 25, 2022
Principal Executive Offices: Tel Aviv, Israel
This filing serves to distribute a press release dated August 24, 2022, regarding the Company's psychedelic-based pharmaceutical collaboration with Clearmind Medicine Inc. Specific sections of the press release are incorporated by reference into the Company's registration statements on Form F-3 and Form S-8.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on operational developments and does not contain financial statements or quantitative financial data.
Material Changes
Operational Development: The Company announced additional positive results for the treatment of cocaine addiction within its collaboration with Clearmind Medicine Inc. This represents a significant milestone in the Company's psychedelic-based pharma pipeline.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates the "Forward-Looking Statements" section from the associated press release (Exhibit 99.1) by reference. The press release highlights positive clinical results but does not provide specific numerical guidance or financial forecasts in this document.
Risks and Contingencies: While the filing references forward-looking statements, it does not explicitly detail specific risks or contingencies within the body of this Form 6-K. Investors are directed to the incorporated press release for full disclosure regarding forward-looking information.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 24, 2022) for detailed clinical data regarding the cocaine addiction treatment results.
- Verify the specific terms of the collaboration with Clearmind Medicine Inc. as referenced in the press release.
- Check the incorporated "Forward-Looking Statements" in the press release for assumptions and risk factors related to the clinical trial outcomes.
- Confirm the status of the Company's registration statements (Form F-3 and Form S-8) to understand how this news impacts future capital raising activities.